Nasal delivery is used as a treatment of local infection in the nasal course & paranasal sinuses such as allergic & non-allergic sinusitis & rhinitis. The nasal drug delivery technique is used as to mitigate the problem of slow absorption of drugs, degradation before reaching the target site, and poor bioavailability. In addition, it helps in resolving issues related to the gastrointestinal tract and first-pass metabolism in liver. The significance of the nasal airway technology is to protect the lungs from hazardous contacts, rather than acting as a delivery route for drugs.
The global nasal drug delivery technology market is driven by rise in demand for alternative routes of drug delivery such as nasal sprays, increase in emphasis on pediatric & geriatric patients, growth in need of easy administration & better efficacy products, rise in demand for home healthcare devices, surge in adoption of self-administration practices, and advanced healthcare set-up. However, patents expiry of several drugs and side effects pertaining to drugs, such as nausea, irritation, and infections, restrain the market growth. Conversely, the development of OTC drugs by many pharmaceutical companies provides lucrative opportunities for market growth, especially for nasal drops and sprays sold as generic OTC drugs.
The global nasal drug delivery technology market is segmented on the basis of dosage form, container, system, therapeutic application, end user, and region. Based on dosage form, it is categorized into sprays, drops & liquids, powders, gels, and others. On the basis of container, it is bifurcated into pressurized containers and non-pressurized containers. Based on system, it is divided into multi-dose systems, bi-dose systems, and unit-dose systems. Based on therapeutic application, it is classified into allergic & non-allergic rhinitis, nose congestion, vaccination, and others. Based on end user, it is divided into home care settings and hospitals. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players operating in this market include Merck & Co., Inc., Novartis AG, Johnson & Johnson, Pfizer Inc., AstraZeneca, AptarGroup, Inc., GlaxoSmithKline plc., Aegis Therapeutics LLC., and Becton, Dickinson and Company.
- The report presents the market analysis of the global nasal drug delivery technology market along with the regional trends and future estimations.
- It provides extensive information about the market segments from 2016 to 2023 to understand the market dynamics.
- The key factors that drive, hamper, or provide opportunities to the market are provided in the report
- Competitive landscape of the industry along with the profile analysis of market players is provided in the report.
Nasal Drug Delivery Technologies Market Key Segments
By Dosage Form
- Drops & Liquids
- Pressurized Containers
- Non-pressurized Containers
- Multi-dose Systems
- Bi-dose Systems
- Unit-dose Systems
By Therapeutic Applications
- Allergic & Non-allergic Rhinitis
- Nose Congestion
By End User
- Home Care Settings
- North America
- Rest of Europe
- Rest of Asia-Pacific
- Saudi Arabia
- South Africa
- Rest of LAMEA